Rituximab is an agent with a variety of immunologic effects mediated thorugh its effects on B-lymphocytes. Unfortunately, there is no effective therapy for severe lung disease caused by scleroderma that is not responding to immunosuppression. Two observational studies, one with 8 and one with 15 patients revealed conflicting results. One very small prospective study with 8 patients who received rituximab and six who had not had been performed and showed encouraging results(Daoussius et al). These remain preliminary findings and more research clearly needs to be conducted.
For Professional version see here